All In Biotech

Drug Trial Radar · NCT06265428

A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer

A Phase III, Multicenter, Open-label, Randomized Study to Compare DB-1303 Versus T-DM1 in Patients With HER2-positive Unresectable/Metastatic Breast Cancer Who Have Been Treated With Trastuzumab and a Taxane (Dynasty-Breast01)

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 228 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

228

Actual

Start

Jan 29, 2024

Primary completion

Dec 2027

Study completion Dec 2028

Sponsor

Lead sponsor
DualityBio Inc.Industry
Sponsor type
Industry
Collaborators
BioNTech SE
First posted
Feb 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to compare efficacy and safety of DB-1303/BNT323 versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer patients previously treated with trastuzumab and taxane.

Conditions

  • HER2-positive Breast Cancer

Interventions

  • DB-1303/BNT323Drug

    Administered I.V.

  • T-DM1Drug

    Administered I.V.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) assessment per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)Time frame: Up to approximately 24 months.

Locations

48 sites in 1 country. Site status is shown where the registry gives one.

  • 015

    Bengbu, Anhui, China

  • 016

    Hefei, Anhui, China

  • 029

    Hefei, Anhui, China

  • 001

    Beijing, Beijing Municipality, China

  • 010

    Beijing, Beijing Municipality, China

  • 038

    Jilin City, Changchun, China

  • 036

    Fuzhou, Fujian, China

  • 037

    Xiamen, Fujian, China

  • 023

    Guangzhou, Guangdong, China

  • 024

    Guangzhou, Guangdong, China

  • 026

    Guangzhou, Guangdong, China

  • 028

    Huizhou, Guangdong, China

  • 017

    Nanning, Guangxi, China

  • 022

    Nanning, Guangxi, China

  • 043

    Haikou, Hainan, China

  • 045

    Baoding, Hebei, China

  • 048

    Shijiazhuang, Hebei, China

  • 020

    Haerbin, Heilongjiang, China

  • 018

    Luoyang, Henan, China

  • 006

    Zhengzhou, Henan, China

  • 005

    Zhengzhou, Henan, China

  • 011

    Wuhan, Hubei, China

  • 009

    Wuhan, Hubei, China

  • 030

    Changsha, Hunan, China

  • 027

    Nanjing, Jiangsu, China

  • 004

    Nanjing, Jiangsu, China

  • 044

    Xuzhou, Jiangsu, China

  • 014

    Nanchang, Jiangxi, China

  • 008

    Changchun, Jilin, China

  • 032

    Dalian, Liaoning, China

  • 040

    Binzhou, Shandong, China

  • 031

    Jinan, Shandong, China

  • 047

    Jinan, Shandong, China

  • 012

    Linyi, Shandong, China

  • 039

    Yantai, Shandong, China

  • 002

    Shanghai, Shanghai Municipality, China

  • 046

    Shanghai, Shanghai Municipality, China

  • 035

    Taiyuan, Shanxi, China

  • 003

    Xi’an, Shanxi, China

  • 007

    Chengdu, Sichuan, China

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.